CB-103
- Generic Name
- CB-103
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C15H18N2O
- CAS Number
- 218457-67-1
- Unique Ingredient Identifier
- Q5BB91JL0V
- Background
CB-103 is under investigation in clinical trial NCT03422679 (Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies).
- Associated Conditions
- -
- Associated Therapies
- -
CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Glenn J. Hanna
- Target Recruit Count
- 10
- Registration Number
- NCT05774899
- Locations
- ๐บ๐ธ
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T-LBL
- First Posted Date
- 2022-07-19
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 2
- Registration Number
- NCT05464836
- Locations
- ๐บ๐ธ
MD Anderson Cancer Center, Houston, Texas, United States
CB-103 Plus NSAI In Luminal Advanced Breast Cancer
- First Posted Date
- 2021-01-19
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- MedSIR
- Target Recruit Count
- 2
- Registration Number
- NCT04714619
- Locations
- ๐ช๐ธ
Hospital Sant Joan de Reus, Reus, Spain
๐ช๐ธComplejo Hospitalario de Jaen, Jaen, Spain
Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2018-02-06
- Last Posted Date
- 2024-01-16
- Lead Sponsor
- Cellestia Biotech AG
- Target Recruit Count
- 79
- Registration Number
- NCT03422679
- Locations
- ๐จ๐ญ
Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
๐ช๐ธVall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
๐ฐ๐ทSeoul National University Hospital, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
ยฉ Copyright 2024. All Rights Reserved by MedPath